Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2026-04-27 Governance Information
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
公司章程
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of Guangdong Winsun Bio-Pharmaceutical Co., Ltd. It contains detailed provisions on company governance, shareholder rights, board structure, share issuance, meetings, and other corporate governance matters. It is a foundational governance document rather than a financial report, earnings release, or announcement. It does not contain financial statements or earnings data, nor is it a notice or announcement of a report. The content aligns with the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2026-04-27 Chinese
董事会薪酬与考核委员会关于2024年股权激励计划第一个解除限售期解除限售条件成就及回购注销部分限制性股票方案的核查意见
Remuneration Information Classification · 95% confidence The document is an official announcement from the Board's Remuneration and Assessment Committee regarding the verification opinions on the achievement of conditions for the first release period of the 2024 equity incentive plan and the repurchase and cancellation of some restricted shares. It discusses compliance with relevant laws and regulations, the status of stock incentives, and the repurchase plan. The content focuses on remuneration-related matters, specifically equity incentives and stock repurchase related to employee compensation plans. There is no indication that this is a full annual report, audit report, earnings release, or other financial report. The document is not a proxy solicitation or voting result announcement. It is a remuneration-related disclosure by the board committee. Therefore, the most appropriate classification is Remuneration Information (DEF 14A). The document length is short and focused on remuneration and stock incentive matters, consistent with DEF 14A filings.
2026-04-27 Chinese
关于2024年股权激励计划第一个解除限售期解除限售条件成就的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding the achievement of the first unlocking condition of the 2024 equity incentive plan. It details the board and supervisory committee meetings, legal opinions, performance assessments, and specifics about the unlocking of restricted shares. The content focuses on the equity incentive plan, stock unlocking, and related corporate governance matters. It is not a financial report, earnings release, or audit report. It is also not a proxy solicitation or voting results announcement. The document is a formal disclosure about management and board decisions related to equity incentives and share restrictions. This fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management, including equity incentive plans and related corporate governance disclosures.
2026-04-27 Chinese
关于购买公司及董事、高级管理人员责任险的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the company's decision to purchase liability insurance for the company and its directors and senior management. It includes details about the insurance plan, the approval process by the board and independent directors, and the submission of the proposal to the shareholders' meeting. There are no financial statements, earnings data, or detailed financial analysis. The document is a formal announcement related to board/management matters, specifically about risk management and insurance for directors and senior management. This fits best under the category of Board/Management Information (MANG), as it concerns decisions and disclosures about the company's board and senior management responsibilities and protections.
2026-04-27 Chinese
2025年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2025年年度权益分派预案公告" which translates to "2025 Annual Equity Distribution Plan Announcement." It discusses the company's plan to distribute cash dividends for the fiscal year 2025, referencing the audited 2025 annual report but not containing the full report itself. The document includes details about dividend amounts, conditions, company bylaws related to profit distribution, and the approval process involving the board and shareholders. It is an announcement of a dividend distribution plan (preliminary proposal) rather than the actual dividend payment notice or the full annual report. The document length is 3759 characters, relatively short and focused on the dividend plan announcement. Therefore, it fits best under the category "Notice of Dividend Amount (DIV)" as it announces the dividend distribution plan and related details for the year 2025.
2026-04-27 Chinese
拟续聘2026年度会计师事务所公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the fiscal year 2026. It details the auditor's background, qualifications, independence, audit fees, and the approval process by the board and audit committee. There are no actual financial statements or audit results included, nor is this a full audit report. The document is relatively short (3017 characters) and serves as a formal announcement of the auditor appointment process rather than the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.